Population Pharmacokinetics and Pharmacodynamics of GSK961081 (Batefenterol), a Muscarinic Antagonist and β2-Agonist, in Moderate-to-Severe COPD Patients: Substudy of a Randomized Trial-Reference-Cited by-同舟云学术

Population Pharmacokinetics and Pharmacodynamics of GSK961081 (Batefenterol), a Muscarinic Antagonist and β2-Agonist, in Moderate-to-Severe COPD Patients: Substudy of a Randomized Trial

Published:2015-08-19 Issue:3 Volume:15 Page:281-291
ISSN:1174-5886
Container-title:Drugs in R&D
language:en
Short-container-title:Drugs R D

Author:

Ambery Claire L.,Wielders Pascal,Ludwig-Sengpiel Andrea,Chan Robert,Riley John H.

Funder

GlaxoSmithKline (GB)

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology

Link

http://link.springer.com/article/10.1007/s40268-015-0104-x/fulltext.html

Reference27 articles.

1. World Health Organization. Health topics: chronic obstructive pulmonary disease. 2015. http://www.who.int/topics/chronic_obstructive_pulmonary_disease/en/ . Accessed 19 Feb 2015.

2. Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of COPD. 2015. http://www.goldcopd.org/guidelines-global-strategy-for-diagnosis-management.html . Accessed 19 Feb 2015.

3. Celli BR, MacNee W. Standards of the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J. 2004;23:932–46.

4. Norris V, Ambery C, Riley T. Pharmacokinetics and pharmacodynamics of GSK961081, a novel inhaled muscarinic antagonist b2-agonist, and fluticasone propionate administered alone, concurrently and as a combination blend formulation in healthy volunteers. Clin Pharmacol Drug Dev. 2014;3:305–13.

5. Cazzola M, Molimard M. The scientific rationale for combining long-acting beta2-agonists and muscarinic antagonists in COPD. Pulm Pharmacol Ther. 2010;23:257–67.

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Calmodulin Triggers Activity-Dependent rRNA Biogenesis via Interaction with DDX21;The Journal of Neuroscience;2024-07-26

2. Assessment of the predictive capability of modelling and simulation to determine bioequivalence of inhaled drugs: A systematic review;DARU Journal of Pharmaceutical Sciences;2022-01-30

Long-Acting Muscarinic Antagonists Under Investigational to Treat Chronic Obstructive Pulmonary Disease

;Journal of Experimental Pharmacology;2020-12

Ultra Long-Acting β-Agonists in Chronic Obstructive Pulmonary Disease

;Journal of Experimental Pharmacology;2020-12

5. Pharmacokinetics, Excretion, and Mass Balance of [14 C]-Batefenterol Following a Single Microtracer Intravenous Dose (Concomitant to an Inhaled Dose) or Oral Dose of Batefenterol in Healthy Men;Clinical Pharmacology in Drug Development;2018-09-19